|
|
|
|
 |
Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute |
| Companies mentioned in this article: |
|
Scripps Research Institute |
|
| 5/14/2008 @ 9:25 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) , a biopharmaceutical company focused on oncology, and The Scripps Research Institute, a non-profit biomedical research organization, today announced that an agreement has been executed licensing classes of protein kinase inhibitors for the treatment of human diseases, including cancer. The research collaboration was initiated in 2005 at Scripps Florida, a division of the Institute located in Palm Beach County, and later broadened to include The Scripps Research Institute, La Jolla, California. The license includes compounds that were discovered by Scripps Research in collaboration with Poniard.
"We are pleased with the productive collaboration with Scripps Research, and we are continuing to build on the progress of this collaboration to identify compounds that have significant potential to treat cancer and other diseases," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We are on target with our program at Poniard to identify a kinase drug candidate that has the potential to be combined with our lead product picoplatin, which is currently in a Phase 3 registration study for small cell lung cancer."
Kinases regulate signaling networks and thereby control cellular properties such as proliferation, invasion, survival and differentiation. Mutations or altered expression of kinases can lead to malignant properties. In oncology, kinase inhibitors have been shown to impact the growth, survival and spread of tumor cells.
"This successful collaboration is consistent with our vision for Scripps Florida, accelerating the pace of discoveries from the laboratory to the treatment of patients," said Richard A. Lerner, M.D., president of The Scripps Research Institute. "We look forward to continued progress for this program at Poniard."
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Scripps Research is headquartered in La Jolla, California. It also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Currently operating from temporary facilities in Jupiter, Scripps Florida will move to its permanent campus in 2009.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit www.poniard.com/. |
| BioTech / BioMedical / Medical |
|
|
| |
| Tuesday, July 8, 2008 |
 |
|
International Stem Cell Corporation Announces Collaboration with Michigan State University to Study Parthenogenetic Stem Cells Posted 7:47 AM PST
FDA Grants Invitrogen Premarket Approval of Breast Cancer Test Posted 7:42 AM PST
|
| |
| Monday, July 7, 2008 |
|
|
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV Posted 3:06 PM PST
AutoGenomics INFINITI Analyzer Receives Artistic Design Award Posted 6:35 AM PST
|
| |
| Wednesday, July 2, 2008 |
|
|
PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc. Posted 6:37 AM PST
Sequenom Launches iSEQ Application Posted 6:36 AM PST
Sequenom Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares Posted 6:36 AM PST
PURE Bioscience Strengthens Pharmaceutical Development Program Posted 6:33 AM PST
MicroIslet Provides Safety and Efficacy Data Update; No Adverse Events Attributable To MicroIslet-P In Animal Models Posted 6:31 AM PST
|
| |
| Tuesday, July 1, 2008 |
|
|
Metabasis to Present at the Collins Stewart 4th Annual Growth Conference Posted 4:34 PM PST
ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor Posted 1:35 PM PST
The Wellcome Trust Case Control Consortium (WTCCC) Selects Illumina Infinium High-Density (HD) DNA Analysis Products to Study 90,000 Samples Posted 8:04 AM PST
Aethlon Medical Announces Second HIV/AIDS Treatment Site Posted 8:03 AM PST
|
| |
| Monday, June 30, 2008 |
|
|
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial Posted 3:11 PM PST
Invitrogen and the Génome Québec and Montreal Heart Institute Pharmacogenomics Centre Announce Collaboration to Advance Pharmacogenomics Research Posted 2:52 PM PST
Burnham Institute Researchers Link Early Stem Cell Mutation to Autism Posted 2:51 PM PST
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 Posted 6:46 AM PST
Cardium Announces Follow-On Direct Investment by Institutional Investor Posted 6:41 AM PST
Early Results from Ongoing Clinical Study of Hepatitis C Vaccine Delivered by Inovio Biomedical’s Electroporation System Show Increased T-Cell Responses and Reduced Viral Loads Posted 6:31 AM PST
|
| |
| Wednesday, June 25, 2008 |
|
|
$6 Million Grant from NIH Advances Vical RapidResponse DNA Vaccine Platform Posted 8:55 AM PST
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing Posted 8:49 AM PST
Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients Posted 8:49 AM PST
International Stem Cell Corporation Cuts a Deal with BioTime, Inc., and Embryome Sciences, Inc., to Provide Unique Human Stem Cell Lines for Research Use Posted 8:08 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
